Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Decreases Position in HCA Healthcare, Inc. $HCA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its stake in HCA Healthcare, Inc. (NYSE:HCA) by 60.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 200 shares of the company’s stock after selling 300 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in HCA Healthcare were worth $77,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Forum Financial Management LP boosted its position in shares of HCA Healthcare by 6.3% in the second quarter. Forum Financial Management LP now owns 1,098 shares of the company’s stock worth $421,000 after buying an additional 65 shares during the period. Ethic Inc. boosted its position in shares of HCA Healthcare by 1.7% in the second quarter. Ethic Inc. now owns 9,563 shares of the company’s stock worth $3,627,000 after buying an additional 159 shares during the period. Caliber Wealth Management LLC KS lifted its stake in shares of HCA Healthcare by 6.3% in the second quarter. Caliber Wealth Management LLC KS now owns 8,180 shares of the company’s stock worth $3,134,000 after acquiring an additional 482 shares in the last quarter. Cookson Peirce & Co. Inc. acquired a new position in shares of HCA Healthcare in the second quarter worth about $239,000. Finally, Greenup Street Wealth Management LLC lifted its stake in shares of HCA Healthcare by 1.5% in the second quarter. Greenup Street Wealth Management LLC now owns 6,231 shares of the company’s stock worth $2,387,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insider Buying and Selling

In related news, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. This trade represents a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

HCA Healthcare Trading Down 0.3%

Shares of HCA Healthcare stock opened at $440.07 on Friday. The business’s 50 day simple moving average is $413.82 and its 200-day simple moving average is $380.88. The stock has a market capitalization of $102.97 billion, a price-to-earnings ratio of 18.50, a PEG ratio of 1.39 and a beta of 1.40. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $447.09.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping analysts’ consensus estimates of $6.20 by $0.64. The business had revenue of $18.61 billion for the quarter, compared to analysts’ expectations of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The business’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned $5.50 EPS. Sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on HCA. Wall Street Zen upgraded HCA Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Wolfe Research cut HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research note on Monday, July 28th. KeyCorp increased their target price on HCA Healthcare from $370.00 to $465.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Barclays increased their target price on HCA Healthcare from $390.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Finally, The Goldman Sachs Group started coverage on HCA Healthcare in a report on Tuesday, October 14th. They set a “buy” rating and a $470.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, HCA Healthcare presently has a consensus rating of “Moderate Buy” and an average price target of $437.19.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.